Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
221
-
222
-
223
-
224
-
225
Data Sheet 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.docx
Published 2025“…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
-
226
-
227
-
228
-
229
-
230
-
231
Pan-cancer analyses of ACADM expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
232
-
233
-
234
-
235
-
236
-
237
-
238
-
239
Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx
Published 2025“…Background<p>Hyper-IgM syndrome (HIGM) is a genetic immunodeficiency characterized by elevated to normal IgM levels and decreased IgG, IgA, and IgE. The overlapping clinical presentations of different gene mutations complicate diagnosis and management.…”
-
240
Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”